 |
 |
|
|
|
| Thymosin α1 Acetate |
 |
| C129H215N33O55 |
 |
| 62304-98-7 |
 |
| It is clinically used to treat chronic hepatitis B and acts as the vaccine adjuvant of immunity impairer. |
 |
Parameters of Product:
1 .Appearance :White powder
2 .Specific Optical Rotation(c=1,15%HAc) :-80.0~-95.0°
3 .Water Content(Karl Fischer) :≤5.0%
4 .Acetate Content(by HPLC) :≤10.0%
5 .Amino Acid Composition :±10% of theoretical
6 .Purity (by HPLC) :≥98.0%
7 .Single Impurity(by HPLC) :≤1.0%
8 .Peptide Content(by N%) :≥82.0%
9 .Assay(By Anhydrous, Acetic Acid-free ) :95.0~102.0%
10 .Bacterial Endotoxins :≤5EU/mg
|
|
|
|
|
|
